| 000-51598 | 77-0259335 | |
| (Commission File Number) | (IRS Employer Identification No.) |
| 8 Crosby Drive, Bedford, Massachusetts | 01730 | |
| (Address of Principal Executive Offices) | (Zip Code) |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02
Results of Operations and Financial Condition.
Item 9.01
Financial Statements and Exhibits.
99.1
iRobot Corporation
October 21, 2009
By:
/s/ Glen D. Weinstein
Name:
Glen D. Weinstein
Title:
General Counsel and Secretary
|
Contacts:
|
||
|
Elise Caffrey
|
Nancy Smith | |
|
Investor Relations
|
Media Relations | |
|
iRobot Corp.
|
iRobot Corp. | |
|
(781) 430-3003
|
(781) 430-3323 | |
|
ecaffrey@irobot.com
|
nsmith@irobot.com |
| | International home robot revenue in the third quarter of 2009 increased 55 percent from the third quarter of 2008 and comprised half of total home robot revenue in the quarter. | |
| | Government & Industrial Robots division received more than $55 million in orders from the U.S. Government during the quarter and has 100 percent visibility on its full-year revenue expectations. | |
| | In the first nine months of 2009, operating cash flow was $24.6 million, compared with cash used in operations of $0.3 million in the first nine months of 2008, as continued aggressive management led to a $17.9 million reduction of inventory at quarter end versus last year. |
|
Fiscal Year 2009:
|
||
|
Revenue
|
$295 $305 million | |
|
Adjusted EBITDA
|
$15 $18 million | |
|
Earnings Per Share
|
$0.02 $0.06 | |
|
|
||
|
Q4 2009:
|
||
|
Revenue
|
$98 $108 million | |
|
Adjusted EBITDA
|
$7 $10 million | |
|
Earnings Per Share
|
$0.09 $0.13 |
| For the three months ended | For the nine months ended | |||||||||||||||
| September 26, | September 27, | September 26, | September 27, | |||||||||||||
| 2009 | 2008 | 2009 | 2008 | |||||||||||||
|
Revenue
|
||||||||||||||||
|
Product revenue
|
$ | 69,080 | $ | 87,224 | $ | 171,380 | $ | 198,475 | ||||||||
|
Contract revenue
|
9,539 | 5,191 | 25,515 | 18,444 | ||||||||||||
|
Total
|
78,619 | 92,415 | 196,895 | 216,919 | ||||||||||||
|
Cost of Revenue
|
||||||||||||||||
|
Product revenue
|
46,415 | 58,371 | 116,952 | 138,948 | ||||||||||||
|
Contract revenue
|
8,009 | 5,114 | 23,133 | 17,213 | ||||||||||||
|
Total
|
54,424 | 63,485 | 140,085 | 156,161 | ||||||||||||
|
Gross Margin
|
24,195 | 28,930 | 56,810 | 60,758 | ||||||||||||
|
Operating Expense
|
||||||||||||||||
|
Research & development
|
3,159 | 4,940 | 10,633 | 13,631 | ||||||||||||
|
Selling & marketing
|
9,514 | 10,522 | 27,420 | 35,451 | ||||||||||||
|
General & administrative
|
7,420 | 7,578 | 21,915 | 21,696 | ||||||||||||
|
Total
|
20,093 | 23,040 | 59,968 | 70,778 | ||||||||||||
|
Operating income (loss)
|
4,102 | 5,890 | (3,158 | ) | (10,020 | ) | ||||||||||
|
Other income (expense), net
|
112 | 180 | (96 | ) | 917 | |||||||||||
|
Pre-tax income (loss)
|
4,214 | 6,070 | (3,254 | ) | (9,103 | ) | ||||||||||
|
Income tax expense (benefit)
|
1,620 | 2,218 | (1,452 | ) | (4,437 | ) | ||||||||||
|
Net income (loss)
|
$ | 2,594 | $ | 3,852 | $ | (1,802 | ) | $ | (4,666 | ) | ||||||
|
|
||||||||||||||||
|
Net income (loss) per common share:
|
||||||||||||||||
|
Basic
|
$ | 0.10 | $ | 0.16 | $ | (0.07 | ) | $ | (0.19 | ) | ||||||
|
Diluted
|
$ | 0.10 | $ | 0.15 | $ | (0.07 | ) | $ | (0.19 | ) | ||||||
|
|
||||||||||||||||
|
Shares used in Per Common Share Calculations:
|
||||||||||||||||
|
Basic
|
25,025 | 24,712 | 24,974 | 24,614 | ||||||||||||
|
Diluted
|
25,670 | 25,536 | 24,974 | 24,614 | ||||||||||||
|
|
||||||||||||||||
|
Stock-based compensation included in above figures:
|
||||||||||||||||
|
Cost of product revenue
|
$ | 267 | $ | 184 | $ | 758 | $ | 554 | ||||||||
|
Cost of contract revenue
|
139 | 127 | 464 | 300 | ||||||||||||
|
Research & development
|
89 | 131 | 187 | 226 | ||||||||||||
|
Selling & marketing
|
351 | 305 | 1,006 | 733 | ||||||||||||
|
General & administrative
|
1,016 | 1,090 | 2,944 | 2,495 | ||||||||||||
|
Total
|
$ | 1,862 | $ | 1,837 | $ | 5,359 | $ | 4,308 | ||||||||
| September 26, | December 27, | |||||||
| 2009 | 2008 | |||||||
|
|
||||||||
|
Assets
|
||||||||
|
|
||||||||
|
Cash and equivalents
|
$ | 62,747 | $ | 40,852 | ||||
|
Accounts receivable, net
|
43,934 | 35,930 | ||||||
|
Unbilled revenues
|
2,537 | 2,014 | ||||||
|
Inventory
|
24,653 | 34,560 | ||||||
|
Deferred tax assets
|
7,295 | 7,299 | ||||||
|
Other current assets
|
4,430 | 3,340 | ||||||
|
|
||||||||
|
Total current assets
|
145,596 | 123,995 | ||||||
|
Property, plant and equipment, net
|
20,401 | 22,929 | ||||||
|
Deferred tax assets
|
4,508 | 4,508 | ||||||
|
Other assets
|
11,877 | 12,246 | ||||||
|
|
||||||||
|
Total assets
|
$ | 182,382 | $ | 163,678 | ||||
|
|
||||||||
|
|
||||||||
|
Liabilities and stockholders equity
|
||||||||
|
|
||||||||
|
Accounts payable
|
$ | 27,787 | $ | 19,544 | ||||
|
Accrued expenses
|
11,672 | 10,989 | ||||||
|
Accrued compensation
|
10,846 | 6,393 | ||||||
|
Deferred revenue and customer advances
|
4,244 | 2,632 | ||||||
|
|
||||||||
|
Total current liabilities
|
54,549 | 39,558 | ||||||
|
|
||||||||
|
Long term liabilities
|
4,122 | 4,444 | ||||||
|
|
||||||||
|
Stockholders equity
|
123,711 | 119,676 | ||||||
|
|
||||||||
|
Total liabilities and stockholders equity
|
$ | 182,382 | $ | 163,678 | ||||
|
|
||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| September 26, | September 27, | September 26, | September 27, | |||||||||||||
| 2009 | 2008 | 2009 | 2008 | |||||||||||||
|
Cash flows from operating activities:
|
||||||||||||||||
|
Net income (loss)
|
$ | 2,594 | $ | 3,852 | $ | (1,802 | ) | $ | (4,666 | ) | ||||||
|
Adjustments to reconcile net income (loss)
to net cash provided by (used in) operating
activities:
|
||||||||||||||||
|
Depreciation and amortization
|
2,289 | 1,844 | 6,153 | 5,135 | ||||||||||||
|
Loss on disposal of property and equipment
|
74 | 12 | 176 | 80 | ||||||||||||
|
Stock-based compensation
|
1,862 | 1,837 | 5,359 | 4,308 | ||||||||||||
|
In-process research and development
relating to acquisition of Nekton
Research LLC
|
| 200 | | 200 | ||||||||||||
|
Benefit from deferred tax assets
|
164 | | (347 | ) | | |||||||||||
|
Non-cash director deferred compensation
|
33 | 24 | 99 | 71 | ||||||||||||
|
Changes in operating assets and liabilities
(use) source
|
||||||||||||||||
|
Accounts receivable
|
(12,643 | ) | (21,598 | ) | (8,004 | ) | 1,830 | |||||||||
|
Unbilled revenue
|
922 | (82 | ) | (523 | ) | (28 | ) | |||||||||
|
Inventory
|
3,985 | 692 | 9,907 | 2,626 | ||||||||||||
|
Other assets
|
1,052 | 1,186 | (1,111 | ) | (6,930 | ) | ||||||||||
|
Accounts payable
|
6,679 | 7,192 | 8,243 | (13,540 | ) | |||||||||||
|
Accrued expenses
|
706 | 1,226 | 673 | 1,405 | ||||||||||||
|
Accrued compensation
|
3,819 | 1,481 | 4,453 | 3,503 | ||||||||||||
|
Deferred revenue
|
1,270 | 1,755 | 1,612 | 1,127 | ||||||||||||
|
Change in long term liabilities
|
(107 | ) | (107 | ) | (322 | ) | 4,552 | |||||||||
|
Net cash provided by (used in) operating
activities
|
12,699 | (486 | ) | 24,566 | (327 | ) | ||||||||||
|
|
||||||||||||||||
|
Cash flows from investing activities:
|
||||||||||||||||
|
Purchase of property and equipment
|
(953 | ) | (1,312 | ) | (3,401 | ) | (13,589 | ) | ||||||||
|
Purchase of Nekton Research LLC, net of cash
received
|
| (9,745 | ) | | (9,745 | ) | ||||||||||
|
Purchases of investments
|
| | | (29,997 | ) | |||||||||||
|
Sales of investments
|
| 1,300 | | 30,350 | ||||||||||||
|
Net cash used in investing activities
|
(953 | ) | (9,757 | ) | (3,401 | ) | (22,981 | ) | ||||||||
|
|
||||||||||||||||
|
Cash flows from financing activities:
|
||||||||||||||||
|
Proceeds from stock option exercises
|
36 | 176 | 495 | 908 | ||||||||||||
|
Income tax withholding payment associated
with restricted stock vesting
|
(67 | ) | | (76 | ) | | ||||||||||
|
Borrowings under revolving line of credit
|
| 5,500 | | 5,500 | ||||||||||||
|
Tax benefit of excess stock based
compensation deductions
|
43 | 322 | 311 | 680 | ||||||||||||
|
Net cash provided by financing activities
|
12 | 5,998 | 730 | 7,088 | ||||||||||||
|
|
||||||||||||||||
|
Net increase (decrease) in cash and cash
equivalents
|
11,758 | (4,245 | ) | 21,895 | (16,220 | ) | ||||||||||
|
Cash and cash equivalents, at beginning of
period
|
50,989 | 14,760 | 40,852 | 26,735 | ||||||||||||
|
Cash and cash equivalents, at end of period
|
$ | 62,747 | $ | 10,515 | $ | 62,747 | $ | 10,515 | ||||||||
Supplemental Information
(unaudited)
For the three months ended
For the nine months ended
September 26,
September 27,
September 26,
September 27,
2009
2008
2009
2008
$
44,331
$
53,626
$
111,253
$
125,424
55
24,749
33,598
60,127
73,051
9,539
5,191
25,515
18,389
$
78,619
$
92,415
$
196,895
$
216,919
$
5,489
$
6,777
$
17,178
$
22,514
$
5,368
$
5,977
$
14,299
$
11,351
$
22,017
$
14,203
$
59,296
$
42,784
$
4,435
$
4,360
$
8,907
$
5,570
$
143
$
138
$
153
$
150
$
122
$
87
$
100
$
96
$
13,450
$
14,867
$
33,711
$
33,695
10,745
14,063
23,099
27,063
$
24,195
$
28,930
$
56,810
$
60,758
289
355
664
761
159
319
460
645
$
71,038
$
36,621
$
71,038
$
36,621
54
48
54
48
7.5
5.5
7.5
5.5
$
12,699
$
(486
)
$
24,566
$
(327
)
514
505
514
505
| For the three months ended | For the nine months ended | |||||||||||||||
| September 26, | September 27, | September 26, | September 27, | |||||||||||||
| 2009 | 2008 | 2009 | 2008 | |||||||||||||
|
|
||||||||||||||||
|
Net income (loss)
|
$ | 2,594 | $ | 3,852 | $ | (1,802 | ) | $ | (4,666 | ) | ||||||
|
|
||||||||||||||||
|
Interest income, net
|
(5 | ) | (205 | ) | (41 | ) | (1,034 | ) | ||||||||
|
Income tax expense (benefit)
|
1,620 | 2,218 | (1,452 | ) | (4,437 | ) | ||||||||||
|
Depreciation
|
2,150 | 1,803 | 5,763 | 5,094 | ||||||||||||
|
Amortization
|
139 | 41 | 390 | 41 | ||||||||||||
|
|
||||||||||||||||
|
EBITDA
|
6,498 | 7,709 | 2,858 | (5,002 | ) | |||||||||||
|
|
||||||||||||||||
|
Stock-based compensation expense
|
1,862 | 1,837 | 5,359 | 4,308 | ||||||||||||
|
|
||||||||||||||||
|
Adjusted EBITDA
|
$ | 8,360 | $ | 9,546 | $ | 8,217 | $ | (694 | ) | |||||||